We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 3

1.
Figure 1

Figure 1. From: Novel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes.

Study diagram depicting the number of subjects studied under each condition and the study lengths.

Jessica R. Castle, et al. Diabetes Care. 2010 June;33(6):1282-1287.
2.
Figure 2

Figure 2. From: Novel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes.

Example of data taken from a closed-loop study. Venous blood glucose is noted by black diamonds, insulin delivery rate by a gray line, and glucagon delivery rate by rectangles. Note that glucagon is delivered by algorithm in the late postprandial period at times of impending hypoglycemia. Overt hypoglycemia is avoided without the use of carbohydrate supplementation.

Jessica R. Castle, et al. Diabetes Care. 2010 June;33(6):1282-1287.
3.
Figure 3

Figure 3. From: Novel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes.

Summary of glucose levels (means ± SE), insulin delivery rate, and, for glucagon studies, the glucagon delivery rate. Venous blood glucose is noted by gray diamonds, insulin delivery rate by a black line, glucagon delivery rate by a light gray line, and meals by black triangles. A: Composite of eight insulin plus placebo studies. B: Composite of seven insulin plus high-gain glucagon studies. Insulin delivery and overall glycemic control were similar in both conditions.

Jessica R. Castle, et al. Diabetes Care. 2010 June;33(6):1282-1287.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk